Advertisement

Drug Safety

, Volume 40, Issue 8, pp 647–649 | Cite as

Good Intentions, But What About Unintended Consequences?

  • Helen C. KalesEmail author
  • Donovan T. Maust
Commentary
  • 231 Downloads

The greatest thing that science teaches you is the law of unintended consequences.

- Ann Druyan

Managing the behavioral and psychological symptoms of dementia (BPSD) that accompany cognitive decline—including agitation, anxiety, depression, aggression, sleep problems, and socially inappropriate behaviors—is one of the biggest challenges of day-to-day care. These symptoms are associated with many of the negative outcomes of dementia, including hospitalizations; increased placement in nursing homes; caregiver stress, including depression and lost income; and decreased quality of life for both patient and caregiver. Despite the fact that, in the USA, no drugs have been approved by the US FDA for BPSD, the current mainstay of treatment is the (primarily off-label) use of psychotropic medications [1, 2]. Of the agents used to treat BPSD, atypical antipsychotics have the strongest evidence base, although their benefits are moderate at best (effect size 0.13–0.16) [3]. Any such benefits must...

Notes

Compliance with Ethical Standards

Funding

No sources of funding were used to assist in the preparation of this commentary.

Conflicts of interest

Helen Kales and Donovan Maust have no conflicts of interest that are directly relevant to this commentary.

References

  1. 1.
    Jeste D, Blazer D, Casey D, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33(5):957–70.CrossRefGoogle Scholar
  2. 2.
    Kolanowski A, Fick D, Waller JL, Ahern F. Outcomes of antipsychotic drug use in community-dwelling elders with dementia. Arch Psychiatr Nurs. 2006;20(5):217–25.CrossRefGoogle Scholar
  3. 3.
    Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369.CrossRefGoogle Scholar
  4. 4.
    Centers for Medicare and Medicaid Services. Initiative to Improve Behavioral Health and Reduce the Use of Antipsychotic Medications in Nursing Homes Residents Video Streaming Event. 2013. http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/NursingHomeQualityInits/Spotlight.html. Accessed 26 June 2017.
  5. 5.
    Office of Government Accountability. Antipsychotic drug use: HHS has initiatives to reduce use among older adults in nursing homes, but should expand efforts to other settings. Washington, DC: Government AccountabilIty Office; 2015.Google Scholar
  6. 6.
    Stocks SJ, Kontopantelis E, Webb RT, Avery AJ, Burns A, Ashcroft DM. Antipsychotic prescribing to patients diagnosed with dementia without a diagnosis of psychosis in the context of national guidance and drug safety warnings: longitudinal study in UK general practice. Drug Saf. 2017. doi: 10.1007/s40264-017-0538-x (Epub 2017).CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Donegan K, Fox N, Black N, Livingston G, Banerjee S, Burns A. Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study. Lancet Public Health. 2017;2(3):e149–56.CrossRefGoogle Scholar
  8. 8.
    Kales H, Zivin K, Kim H, et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatr. 2011;68(2):190–7.CrossRefGoogle Scholar
  9. 9.
    Vasudev A, Shariff SZ, Liu K, Burhan AM, Herrmann N, Leonard S, Mamdani M. Trends in psychotropic dispensing among older adults with dementia living in long-term care facilities: 2004–2013. Am J Geriatr Psychiatry. 2015;23(12):1259–69.CrossRefGoogle Scholar
  10. 10.
    Peisah C, Chan D, McKay R, Kurrle S, Reutens S. Practical guidelines for the acute emergency sedation of the severely agitated older patient. Intern Med J. 2011;41(9):651–7.CrossRefGoogle Scholar
  11. 11.
    Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169(1):71.CrossRefGoogle Scholar
  12. 12.
    Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438–45.CrossRefGoogle Scholar
  13. 13.
    Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682–91.CrossRefGoogle Scholar
  14. 14.
    Sepehry AA, Lee PE, Hsiung GYR, Beattie BL, Jacova C. Effect of selective serotonin reuptake inhibitors in Alzheimer’s disease with comorbid depression. Drugs Aging. 2012;29(10):793–806.CrossRefGoogle Scholar
  15. 15.
    Bowblis JR, Crystal S, Intrator O, Lucas JA. Response to regulatory stringency: the case of antipsychotic medication in nursing homes. Health Econ. 2012;21(8):977–93.CrossRefGoogle Scholar
  16. 16.
    Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: Recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762–9.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG (outside the USA) 2017

Authors and Affiliations

  1. 1.Program for Positive Aging, Department of PsychiatryUniversity of MichiganAnn ArborUSA
  2. 2.Department of Veterans AffairsHSR&D Center for Clinical Management Research (CCMR)Ann ArborUSA
  3. 3.Geriatric Research, Education and Clinical Center (GRECC)VA Ann Arbor Healthcare SystemAnn ArborUSA

Personalised recommendations